SEC Form 4 · accession 0001780088-26-000021
Stoke Therapeutics, Inc. · STOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Ticho
Officer — CHIEF MEDICAL OFFICER
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:17 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001623526
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 1, 2026 | S | 3,945 | $30.512 | D | 21,710 | D | |
| Common StockF3 | Sep 1, 2026 | S | 1,600 | $31.0569 | D | 20,110 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.94 to $30.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.20 per share, inclusive.